middle.news
Mayne Pharma sharpens US focus with $55.5 million international sale
8:52am on Friday 6th of November, 2026 AEDT
•
Pharmaceuticals
Read Story
Mayne Pharma sharpens US focus with $55.5 million international sale
8:52am on Friday 6th of November, 2026 AEDT
Key Points
$55.5 million cash sale of Mayne Pharma International
Salisbury manufacturing and CDMO operations transfer to Evaris Pharma
Mayne Pharma retains US Women’s Health, Dermatology and DistributeRx
Deal values the segment at 0.79 times FY26 revenue
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mayne Pharma (ASX:MYX)
OPEN ARTICLE